Get the Stockscreener App
1.855
0.27%
0.005
Tscan Therapeutics Inc stock is traded at $1.855, with a volume of 23,508.
It is up +0.27% in the last 24 hours and up +27.93% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.85
Open:
$1.86
24h Volume:
23,508
Relative Volume:
0.04
Market Cap:
$97.04M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.0363
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
+2.49%
1M Performance:
+27.93%
6M Performance:
-27.54%
1Y Performance:
-74.34%
1-Day Range:
$1.84
$1.9599
1-Week Range:
$1.75
$1.9599
52-Week Range:
$1.02
$7.44
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
880 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.855 | 100.17M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.19 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.14 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.74 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.26 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.39 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Is TScan Therapeutics Inc. a good long term investmentFree Capital Efficiency Planning - Autocar Professional
TScan Therapeutics Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
What analysts say about TScan Therapeutics Inc. stockBreakthrough stock performance - jammulinksnews.com
What drives TScan Therapeutics Inc. stock priceTremendous return rates - jammulinksnews.com
One TScan Therapeutics Insider Raised Stake By 18% In Previous Year - Yahoo.co
Why TScan Therapeutics Inc. stock attracts strong analyst attentionStrategic High Profit Opportunities - Newser
How TScan Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser
What makes TScan Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - Newser
TScan Therapeutics (NASDAQ:TCRX) Rating Increased to Hold at Wall Street Zen - Defense World
Great week for TScan Therapeutics, Inc. (NASDAQ:TCRX) institutional investors after losing 73% over the previous year - simplywall.st
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
TScan Therapeutics (NASDAQ:TCRX) Stock Price Down 4% – Time to Sell? - Defense World
TScan Therapeutics Elects New Directors at Annual Meeting - TipRanks
TScan Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
TScan Therapeutics, Inc.(NasdaqGM: TCRX) dropped from Russell Microcap Growth Index - MarketScreener
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80 - Defense World
Wall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to Sell - Defense World
Bank of America Corp DE Has $456,000 Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Wellington Management Group LLP Boosts Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
ProShare Advisors LLC Makes New $40,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BNP Paribas Financial Markets Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewswire
Cancer Therapy Pioneer TScan Therapeutics Set for Major Presentation at Jefferies Healthcare Conference - Stock Titan
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - Barchart.com
New Data and Deal Flow Signal a Turning Point for Precision-Driv - GuruFocus
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Comparing TScan Therapeutics (NASDAQ:TCRX) and Twist Bioscience (NASDAQ:TWST) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Dimensional Fund Advisors LP Increases Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
4.56%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):